Literature DB >> 17580050

[Prevalence of atrial fibrillation in the Spanish population aged 60 years or more. The PREV-ICTUS study].

Luis Cea-Calvo1, Josep Redón, José V Lozano, Cristina Fernández-Pérez, Juan C Martí-Canales, José L Llisterri, Jorge González-Esteban, José Aznar.   

Abstract

INTRODUCTION AND
OBJECTIVES: The aims of this study were to determine the prevalence of atrial fibrillation in individuals aged 60 years or more in Spain using a random sample of the population and to identify associated factors.
METHODS: An analysis of the PREV-ICTUS study, a randomized cross-sectional population-based study of individuals aged 60 years or more, was carried out. Data on demographic variables, cardiovascular risk factors, and cardiovascular disease were obtained from medical records. The diagnosis of atrial fibrillation was based on the patient's medical history and an electrocardiogram performed during the study.
RESULTS: In the 7108 individuals studied (mean age 71.9 [7.1] years, 53.6% female), the prevalence of atrial fibrillation was 8.5% (95% confidence interval [CI] 7.9-9.2%). It was higher in males (9.3% vs 7.9% in females; P=.036) and increased from 4.2% in individuals aged 60-64 years to 16.5% in those aged 85 years or more (chi-squared test for linear trend, P< .001). Multivariate analysis showed that existing cardiovascular disease, hypertension, age, and left ventricular hypertrophy had the strongest associations with atrial fibrillation. Although there was a strong relationship between hypertension and atrial fibrillation (odds ratio 2.53, 95% CI, 1.60-4.01), no association was found between poor blood pressure control and atrial fibrillation. A weak association with diabetes mellitus was found only when arterial pressure was included in the model, but not when a diagnosis of hypertension was included.
CONCLUSIONS: In this cross-sectional population-based study of elderly individuals, the prevalence of atrial fibrillation was 8.5%, and was strongly associated with existing cardiovascular disease, hypertension, age and left ventricular hypertrophy.

Entities:  

Mesh:

Year:  2007        PMID: 17580050     DOI: 10.1157/13107118

Source DB:  PubMed          Journal:  Rev Esp Cardiol        ISSN: 0300-8932            Impact factor:   4.753


  13 in total

1.  Prevalence of atrial fibrillation in an urban population in India: the Nagpur pilot study.

Authors:  Daljeet Kaur Saggu; Gomathi Sundar; Sandeep G Nair; Varun C Bhargava; Krishnamohan Lalukota; Sridevi Chennapragada; Calambur Narasimhan; Sumeet S Chugh
Journal:  Heart Asia       Date:  2016-04-18

Review 2.  Using Direct Oral Anticoagulants in Patients with Atrial Fibrillation: Assessment, Monitoring and Treatment Reversal.

Authors:  Antoni Martínez-Rubio; Mario DiazNuila Alcazar; Anna Soria Cadena; Roger Martínez-Torrecilla
Journal:  Eur Cardiol       Date:  2016-12

Review 3.  Mechanisms and Drug Development in Atrial Fibrillation.

Authors:  David Calvo; David Filgueiras-Rama; José Jalife
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

4.  Predictors of incident atrial fibrillation and influence of medications: a retrospective case-control study.

Authors:  James A Hodgkinson; Clare J Taylor; F D Richard Hobbs
Journal:  Br J Gen Pract       Date:  2011-06       Impact factor: 5.386

5.  Safety of percutaneous nephrolithotomy in patients on chronic anticoagulant or antiplatelet therapy.

Authors:  C Fernández-Baltar; D Pérez-Fentes; J F Sánchez-García; C García-Freire
Journal:  Urolithiasis       Date:  2018-01-22       Impact factor: 3.436

6.  Gender differences related to the presence of atrial fibrillation in older hypertensive patients.

Authors:  Lorenzo Fácila; Vicente Pallarés; Pedro Morillas; Alberto Cordero; Jose Luis Llisterri; Carlos Sánchis; Jose L Gorriz; Jesus Castillo; Vicente Gil; Josep Redon
Journal:  World J Cardiol       Date:  2013-05-26

7.  Opportunistic detection of atrial fibrillation in subjects aged 65 years or older in primare care: a randomised clinical trial of efficacy. DOFA-AP study protocol.

Authors:  Luis Á Pérula-de-Torres; Miguel Á Martínez-Adell; Virginia González-Blanco; José M Baena-Díez; Enrique Martín-Rioboó; Juan M Parras-Rejano; Jesús González-Lama; Remedios Martín-Alvarez; Roger Ruiz-Moral; José Á Fernández-García; Modesto Pérez-Díaz; Joaquin Ruiz-de-Castroviejo; Carlos Pérula-de-Torres; Antonio Valero-Martín; Ana Roldán-Villalobos; Margarita Criado-Larumbe; Emili Burdoy-Joaquín; Montserrat Coma-Solé; Mercè Cervera-León; Lluís Cuixart-Costa
Journal:  BMC Fam Pract       Date:  2012-10-30       Impact factor: 2.497

8.  Results from the Registry of Atrial Fibrillation (AFABE): Gap between Undiagnosed and Registered Atrial Fibrillation in Adults--Ineffectiveness of Oral Anticoagulation Treatment with VKA.

Authors:  Anna Panisello-Tafalla; Josep Lluís Clua-Espuny; Vicente F Gil-Guillen; Antonia González-Henares; María Lluisa Queralt-Tomas; Carlos López-Pablo; Jorgina Lucas-Noll; Iñigo Lechuga-Duran; Rosa Ripolles-Vicente; Jesús Carot-Domenech; Miquel Gallofré López
Journal:  Biomed Res Int       Date:  2015-07-01       Impact factor: 3.411

9.  Direct vitamin K antagonist anticoagulant treatment health care costs in patients with non-valvular atrial fibrillation.

Authors:  Álvaro Hidalgo-Vega; Elham Askari; Rosa Vidal; Isaac Aranda-Reneo; Almudena Gonzalez-Dominguez; Alexandra Ivanova; Gabriela Ene; Pilar Llamas
Journal:  BMC Health Serv Res       Date:  2014-01-30       Impact factor: 2.655

10.  Burden of disease from atrial fibrillation in adults from seven countries in Latin America.

Authors:  Luz Cubillos; Alexandra Haddad; Andreas Kuznik; Joaquin Mould-Quevedo
Journal:  Int J Gen Med       Date:  2014-09-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.